ANAB — ANAPTYSBIO, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1370053 ·
Last close
$45.61
Market Cap
$1.36B
52W High
$72.36
52W Low
$22.07
ADV30
440,010
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 30,274,000 | — | 19,905,000 | 3,876,000 | 307,043,000 | 135,394,000 | 286,223,000 |
| Mar 2026 | 25,556,000 | — | -34,637,000 | -52,884,000 | 329,684,000 | 248,469,000 | 316,937,000 |
| Dec 2025 | 108,249,000 | — | 66,901,000 | 49,614,000 | 364,395,000 | 138,196,000 | 327,185,000 |
| Sep 2025 | 76,320,000 | — | 34,704,000 | 15,113,000 | 353,098,000 | 109,833,000 | 382,514,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,478,000
Investing CF
$248,168,000
Financing CF
$-102,814,000
CapEx
$-69,000
Dividends Paid
—
Buybacks
$-64,202,000
EPS Diluted TTM
$-1.08
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-825,443,000
Inventory
—
Receivables
$25,747,000
ST Investments
$37,986,000
EBIT TTM
$56,064,000
Pretax Income TTM
$-26,627,000
Interest Exp TTM
$82,691,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$60,042,000
EBITDA
$9,015,000
Free Cash Flow
$8,323,875
Enterprise Value
$1,484,398,464
Total Cash
$152,992,992
Total Debt
$262,386,000
Shares Out
29,729,847
Trailing EPS
$6.52
Book Value
$0.69
ROE
-114.6%
ROA
6.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 234,603,000 | 226,902,000 | -13,232,000 | 364,395,000 | 327,185,000 | 37,210,000 | 19,697,000 |
| Dec 2024 | 91,280,000 | 66,152,000 | -145,231,000 | 483,834,000 | 412,966,000 | 70,868,000 | -135,337,000 |
| Dec 2023 | 17,157,000 | -157,072,000 | -163,619,000 | 452,389,000 | 364,286,000 | 88,103,000 | -120,800,000 |
| Dec 2022 | 10,287,000 | -115,154,000 | -128,724,000 | 610,383,000 | 348,280,000 | 262,103,000 | -73,593,000 |
TTM Snapshot
Revenues TTM
$232,388,000
NetIncome TTM
$-26,787,000
OpCashFlow TTM
—
Assets (Latest)
$329,684,000
Forward EPS
$4.59
Max Pain — expiry 2027-02-19
max pain strike: $40.00 · spot: $47.06 · call oi: 977 · put oi: 289
Expected Move to 2027-02-19:
±$15.85
(33.68%) —
implied range
$31.21 –
$62.91
· ATM straddle on $45.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TYRA | Tyra Biosciences, Inc. | $1.35B | $19.57 | — |
| NUVB | Nuvation Bio Inc. | $1.37B | $3.90 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.32B | $6.02 | — |
| NBTX | Nanobiotix S.A. | $1.39B | $27.45 | — |
| DMRA | Damora Therapeutics, Inc. | $1.40B | $22.56 | — |
News headlines (Yahoo Finance, 1h cache)
AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
2026-11-12 22:05 · Yahoo
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
2026-11-12 21:15 · Yahoo
AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?
2026-10-31 21:17 · Yahoo
Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?
2026-10-30 07:10 · Yahoo
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-27 13:00 · Yahoo
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
2026-10-19 18:18 · Yahoo
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
2026-10-12 20:10 · Yahoo
AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
2026-10-09 04:29 · Yahoo
AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
2026-10-08 23:17 · Yahoo
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
2026-09-26 03:38 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-18 18:56:28 | 2026-11-16 | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | 45.98 | 374580 | 17224593 |